why is gsk stock down

by Austin Dach Published 3 years ago Updated 2 years ago

Why is the GSK share price down 6%?

Apr 08, 2022 · Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GSK. News Sentiment. .

Why has GSK split into two companies?

May 05, 2022 · Check out why GSK Pharma share price is falling today. Get detailed GSK Pharma stock price news and analysis, Dividend, Bonus Issue, Quarterly results information, and more. ... 1 Week: GSK Pharma share price moved down by 3.78%; 1 Month: GSK Pharma share price moved down by 6.19%; 3 Month: GSK Pharma share price moved down by 2.95% ...

How can I get the latest news about GSK?

Apr 16, 2022 · GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GSK shares have increased by 7.6% and is now trading at $42.90. View which stocks have been most impacted by COVID-19.

Is GSK a long-term asset?

GSK. $44.09 -$0.30. Caret Down. -0.7%. Price as of May 6, 2022, 4:00 p.m. ET View Interactive GSK Charts. The Company is a global healthcare group …

Is GSK a good stock to buy?

The financial health and growth prospects of GSK, demonstrate its potential to outperform the market. It currently has a Growth Score of B. Recent price changes and earnings estimate revisions indicate this would not be a good stock for momentum investors with a Momentum Score of F.

What happened to GSK?

The company is now exploring a new location for its global headquarters amid a historic business revamp. GSK will leave its iconic glass-façade corporate headquarters in London, known as the GSK House, after 2023 at the earliest, the British pharma unveiled Monday.

What are prospects for GSK shares worth?

Stock Price Forecast

The 18 analysts offering 12-month price forecasts for GlaxoSmithKline PLC have a median target of 45.55, with a high estimate of 55.35 and a low estimate of 35.01. The median estimate represents a +5.16% increase from the last price of 43.31.

Is GlaxoSmithKline undervalued?

These figures are just a handful of the metrics value investors tend to look at, but they help show that GlaxoSmithKline and Pfizer are likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, GSK and PFE feels like a great value stock at the moment.Feb 14, 2022

What will happen to GSK shares?

A circular is expected to be sent to GSK shareholders in connection with approval of the proposed demerger and separation in June 2022, alongside publication of a prospectus in connection with the listing of Haleon. A shareholder vote for approval and subsequent demerger is expected in July 2022.

Is GSK working on Covid vaccine?

Sanofi and GSK today announce that they intend to submit data from both their booster and Phase 3 efficacy trials as the basis for regulatory applications for a COVID-19 vaccine.Feb 23, 2022

Is GSK overvalued?

PB vs Industry: GSK is overvalued based on its PB Ratio (5.4x) compared to the GB Pharmaceuticals industry average (3.6x).

Is GSK a hold?

The GlaxoSmithKline PLC stock holds several negative signals and despite the positive trend, we believe GlaxoSmithKline PLC will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

What is the intrinsic value of GSK?

As of today (2022-04-09), GlaxoSmithKline's Intrinsic Value: Projected FCF is $47.25. The stock price of GlaxoSmithKline is $46.64.

Will GSK cut dividend?

In July 2022, the company aims to complete the de-merger and listing of Haleon, its GlaxoSmithKline, a top pick for UK income investors, will reduce its dividend after spinning out its consumer healthcare business.Apr 22, 2022

Is GSK a good dividend stock?

Over the last three years, GSK's dividend payout has grown at a 10.38% CAGR. Its four-year average dividend yield is 5.27%, and its current dividend translates to a 4.91% yield.

Is GSK publicly traded?

The Stock Is Up.

What's GSK Pharma share price today and what are GSK Pharma share returns ?

As on 17 Mar, 2022, 03:49 PM IST GSK Pharma share price was down by 0.04% basis the previous closing price of Rs 1,572.2. GSK Pharma share price wa...

What's the market capitalization of GSK Pharma?

Within the Pharmaceuticals sector, GSK Pharma stock has a market cap rank of 15. GSK Pharma has a market cap of Rs 26,622.16 Cr.

Should I buy, sell or hold GSK Pharma?

As per Refinitiv (erstwhile Thomson Reuters), overall mean recommendation by 7 analysts for GSK Pharma stock is to Hold. Recommendation breakup is...

What has been highest price of GSK Pharma share in last 52 weeks?

In last 52 weeks GSK Pharma share had a high price of Rs 1,918.75 and low price of Rs 1,376.00

Who are peers to compare GSK Pharma share price?

Top 5 Peers for GSK Pharma are Pfizer Ltd., Sanofi India Ltd., Abbott India Ltd., Procter & Gamble Health Ltd. and AstraZeneca Pharma India Ltd.

Who are the key owners of GSK Pharma stock?

Promoter,DII and FII owns 75.0, 5.59 and 6.95 shares of GSK Pharma as on 31 Dec 2021 There is no change in promoter holding from 30 Sep 2021 to 31...

What are the key metrics to analyse GSK Pharma Share Price?

Key Metrics for GSK Pharma are: PE Ratio of GSK Pharma is 54.33 Earning per share of GSK Pharma is 28.92 Price/Sales ratio of GSK Pharma is 7.63 Pr...

Is GlaxoSmithKline a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlaxoSmithKline in the last twelve months. There are currently 1 sell rat...

How has GlaxoSmithKline's stock price been impacted by Coronavirus?

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organizati...

Are investors shorting GlaxoSmithKline?

GlaxoSmithKline saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 6,900,000 shares,...

When is GlaxoSmithKline's next earnings date?

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, April 27th 2022. View our earnings forecast for Gla...

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (NYSE:GSK) released its earnings results on Wednesday, February, 9th. The pharmaceutical company reported $0.69 EPS for the qua...

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline declared a quarterly dividend on Wednesday, February 9th. Investors of record on Friday, February 25th will be paid a dividend of $...

Is GlaxoSmithKline a good dividend stock?

GlaxoSmithKline pays an annual dividend of $2.46 per share and currently has a dividend yield of 6.07%. GSK has a dividend yield higher than 75% of...

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the following people: Emma N. Walmsley , Chief Executive Officer & Executive Director Iain James Macka...

Who are some of GlaxoSmithKline's key competitors?

Some companies that are related to GlaxoSmithKline include Roche (RHHBY) , Pfizer (PFE) , AbbVie (ABBV) , Eli Lilly and (LLY) , Novo Nordisk A...

What is GlaxoSmithKline Pharmaceuticals?

GlaxoSmithKline Pharmaceuticals Ltd., incorporated in the year 1924, is a Large Cap company (having a market cap of Rs 25,359.24 Crore) operating in Pharmaceuticals sector. GlaxoSmithKline Pharmaceuticals Ltd. key Products/Revenue Segments include Pharmaceuticals, Service Income and Other Operating Revenue for the year ending 31-Mar-2021.

What is a stock score?

Stock Score is the Average Score from Stock Reports Plus by Refinitiv which combines quantitative analysis of widely used investment decision making tools. This score is on a 10 point scale (1 is lowest and 10 being the highest, NR indicates No-rating is available)

What is the ranking of a company within its sector based on?

This is the ranking of a company within its sector based on MCap or Market capitalization. Higher the market capitalization of a company, higher the rank it is assigned.

What is face value of stock?

Face value of a stock is the value ascribed to the stock as per the balance sheet of the company. The dividend declared by a company is usually declared as a percentage of face value. (₹) 10.00.

How much is GSK stock worth in 2020?

GlaxoSmithKline's stock was trading at $39.87 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, GSK stock has decreased by 1.6% and is now trading at $39.23. View which stocks have been most impacted by COVID-19.

What is the GSK symbol?

GlaxoSmithKline trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

What is the dividend payout ratio for GlaxoSmithKline?

Based on earnings estimates, GlaxoSmithKline will have a dividend payout ratio of 69.23% next year. This indicates that GlaxoSmithKline will be able to sustain or increase its dividend. View GlaxoSmithKline's dividend history.

How much does GlaxoSmithKline make?

GlaxoSmithKline has a market capitalization of $105.63 billion and generates $43.79 billion in revenue each year. The pharmaceutical company earns $7.38 billion in net income (profit) each year or $2.98 on an earnings per share basis.

What is the P/E ratio of GlaxoSmithKline?

The P/E ratio of GlaxoSmithKline is 17.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 24.33.

What is GlaxoSmithKline?

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

When will GlaxoSmithKline release its next quarterly earnings?

GlaxoSmithKline is scheduled to release its next quarterly earnings announcement on Wednesday, July 28th 2021. View our earnings forecast for GlaxoSmithKline.

When will GSK earnings call end?

GSK earnings call for the period ending June 30, 2021.

How much did GlaxoSmithKline stock drop in 2016?

Is GlaxoSmithKline's Stock a Bargain After Dropping 4.8% in 2016?

Who does GlaxoSmithKline take on?

GlaxoSmithKline takes on Pfizer, and Biogen battles Celgene in this healthcare edition of Industry Focus.

How many articles has The Fool written on GlaxoSmithKline?

The Fool has written over 1000 articles on GlaxoSmithKline.

How much is GlaxoSmithKline stock worth in 2021?

The GlaxoSmithKline PLC stock price gained 0.48% on the last trading day (Friday, 9th Jul 2021), rising from $39.97 to $40.16. During the day the stock fluctuated 0.68% from a day low at $40.00 to a day high of $40.27. The price has risen in 7 of the last 10 days and is up by 1.16% over the past 2 weeks. Volume fell on the last day by -11 thousand shares and in total, 3 million shares were bought and sold for approximately $122.19 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

What is the price target for GSK in 2021?

On Nov 08, 2021 "UBS Group" gave "" rating for GSK. The price target was changed from $42.83 to 1.5% .

Is GlaxoSmithKline stock a sell signal?

The GlaxoSmithKline PLC stock holds a sell signal from the short-term moving average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term moving average at approximately $42.02. On a fall, the stock will find some support from the long-term average at approximately $41.01. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Volume is rising along with the price. This is considered to be a good technical signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on Wednesday, November 03, 2021, and so far it has fallen -4.43%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD).

When did GSK split?

The decision to divide the company in two came at the end of 2018 after GSK announced a £9.8 billion consumer health joint venture with US rival Pfizer.

Can you short GSK with IG?

You can go long or short GSK with IG using derivatives like CFDs and spread bet s.

What is the symbol for GSK?

GlaxoSmithKline PLC is a American stock, trading under the symbol GSK-N on the New York Stock Exchange (GSK). It is usually referred to as NYSE:GSK or GSK-N.

Where is GSK located?

GlaxoSmithKline plc is a British pharmaceutical company headquartered in Brentford, London. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world's sixth largest ...

Why bother with the UK?

They're already slumping, burdened by near-zero interest rates. Better to look at a long-term investment like GlaxoSmithKline (GSK), traded in New York as well as London. Robert Lauzon warns that a hard Brexit would pressure the UK pound and, by extension, GSK's bottom line, though he considers the pharma company fine overall with its dividend at 4.27% (New York) or 5.16% (London). GSK spun-off a US$12.7 billion consumer healthcare company with Pfizer to refocused on pharmaceuticals and growth. Paul McDonald views this is a likely long-term asset. Since September, four analysts have upgraded GSK, three of them to a buy. Like so many British stocks, GSK faces post-Brexit risk, but it's worth considering for the long run.

Which is better, GSK or Teva?

TEVA vs. GSK Teva is in turnaround with a lot of debt to pay off. They need a boast from their future products moving forward. GSK is higher quality with higher credit rating, and lack Teva's debt woes. GSK is the better bet.

What does a high stock score mean for GlaxoSmithKline?

Stockchase rating for GlaxoSmithKline PLC is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Why does my stock price drop?

Earnings reports or recent company news can cause the stock price to drop . Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Why is the drug industry under pressure?

The whole drug sector is under pressure, because every country is managing costs, including America. It's a cash flow industry struggling to maintain growth. Revenues are flatlining. But it's a defensive sector with solid, growing dividends, so he's reluctant to sell them.

Who is the CEO of GlaxoSmithKline?

CEO Emma Walmsley intends for vaccines and certain treatments, specifically for HIV, to play a larger role in GlaxoSmithKline's future. The company is ramping up research and development in HIV and oncology to tighten focus and continue building its pipeline of products.

Is GlaxoSmithKline's earnings down?

Pricing pressure, mainly hitting its respiratory drugs, contributed to the shortfall. The company is now forecasting 2020 adjusted profit to be down as much as 4%.

Does GlaxoSmithKline have Clover?

That means GlaxoSmithKline will provide Clover with its proprietary adjuvants, compounds that enhance the effectiveness of vaccines. When it became clear that GlaxoSmithKline is not, as of now, developing its own vaccine, shares dropped.

Does Anne Burdakin have a position in any of the stocks mentioned?

Anne Burdakin has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.